Technical Analysis for GRAY - Graybug Vision, Inc.

Grade Last Price % Change Price Change
grade D 14.8 2.00% 0.29
GRAY closed up 2.0 percent on Friday, October 23, 2020, on 39 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical GRAY trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Hot IPO Pullback Bullish Swing Setup 2.00%
Bearish Engulfing Bearish -6.03%
Pocket Pivot Bullish Swing Setup -9.26%
Doji - Bearish? Reversal -9.26%
Hot IPO Pullback Bullish Swing Setup -6.92%
Outside Day Range Expansion -6.92%
Hot IPO Pullback Bullish Swing Setup -3.77%
Up 3 Days in a Row Strength -8.47%
Up 4 Days in a Row Strength -8.47%
Older End-of-Day Gignals for GRAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% 2 days ago
Up 3% 3 days ago
Up 2% 3 days ago
Up 1% 3 days ago
Down 2 % 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.
Medicine Clinical Medicine Diseases Ophthalmology Macular Degeneration Wet Age Related Macular Degeneration Blindness Diabetic Retinopathy Macular Edema Diabetic Macular Edema Retinopathy Macula Of Retina Intravitreal Administration

Is GRAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.69
52 Week Low 12.5
Average Volume 136,305
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 14.72
10-Day Moving Average 15.47
Average True Range 1.40
ADX 0.0
+DI 15.04
-DI 19.30
Chandelier Exit (Long, 3 ATRs ) 16.49
Chandelier Exit (Short, 3 ATRs ) 16.70
Upper Bollinger Band 17.00
Lower Bollinger Band 12.44
Percent B (%b) 0.52
BandWidth 30.97
MACD Line 0.39
MACD Signal Line 0.37
MACD Histogram 0.0239
Fundamentals Value
Market Cap 283.5 Million
Num Shares 19.2 Million
EPS
Price-to-Sales 0.00
Price-to-Book 20.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.38
Resistance 3 (R3) 16.35 15.80 16.11
Resistance 2 (R2) 15.80 15.40 15.81 16.02
Resistance 1 (R1) 15.30 15.15 15.55 15.33 15.94
Pivot Point 14.75 14.75 14.88 14.76 14.75
Support 1 (S1) 14.25 14.35 14.50 14.28 13.66
Support 2 (S2) 13.70 14.10 13.71 13.58
Support 3 (S3) 13.20 13.70 13.49
Support 4 (S4) 13.23